Kaletra (Lopinavir 200 mg / Ritonavir 50 mg) – Patient Information (UK)

Note: This page is written for general patient information in the United Kingdom. Individual treatment plans vary. Always follow the advice of your HIV specialist or other qualified healthcare professional.

1) Basic product information

• Medicine: Kaletra
• Active ingredients: Lopinavir 200 mg + Ritonavir 50 mg
• Combination: Fixed-dose combination (taken together)
• Drug class: Protease inhibitor (PI) with a booster
• Common formulation: Oral capsules or oral solution (availability may vary)
• Used for: Treatment of HIV infection in adults and children (age/weight criteria apply)

2) What Kaletra is used for

Kaletra is an antiretroviral medicine used to treat Human Immunodeficiency Virus (HIV). It works as part of a combination regimen (usually with other antiretroviral medicines) to reduce the virus in the body and help protect the immune system.

In the UK, HIV treatment is managed according to guidance from specialist services (including NICE and British HIV Association recommendations). Your clinician will choose the most appropriate combination based on your medical history, resistance testing, other medicines, and your treatment goals.

3) Indications (when it may be appropriate)

Kaletra may be prescribed for:

• HIV-1 infection in adults
• HIV-1 infection in children, depending on age/weight and formulation
• Use when a ritonavir-boosted protease inhibitor is suitable, for example where resistance patterns or prior treatment history support this choice

4) How Kaletra works (mechanism of action)

Lopinavir blocks a key HIV enzyme called HIV protease. HIV protease is required to cut long viral proteins into smaller functional pieces needed for the virus to become infectious. By inhibiting protease, lopinavir helps prevent the production of new mature, infectious HIV particles.

Ritonavir is included mainly to “boost” lopinavir by slowing its breakdown in the liver. This increases and stabilises lopinavir levels in the blood, improving antiviral effectiveness and dosing convenience.

5) Pharmacokinetics (how the body handles it)

Understanding pharmacokinetics (PK) helps explain why dosing and timing matter.

• Absorption: Lopinavir/ritonavir is absorbed from the gut. Food can improve absorption (details below).
• Distribution: The medicines distribute into body tissues; levels are influenced by liver metabolism and drug interactions.
• Metabolism: Lopinavir is primarily metabolised in the liver (largely via CYP3A enzymes). Ritonavir strongly affects CYP3A activity, which changes exposure to many other medicines.
• Elimination: Metabolites are eliminated mainly via the biliary route (through faeces).
• Steady state: With regular dosing, drug levels reach a stable (“steady-state”) pattern after repeated doses.

Practical implication: Because ritonavir affects metabolism, drug–drug interactions are a key consideration with Kaletra.

6) Typical use and treatment goals

Kaletra is used as part of a combination antiretroviral regimen. The goal is to:

• Reduce viral load (make HIV levels in blood very low)
• Increase or maintain CD4 cells (support immune function)
• Prevent disease progression and reduce transmission risk when viral suppression is achieved

Your clinician may adjust your regimen based on:

• Results of viral load and CD4 count monitoring
• Potential drug resistance (especially if you have previously taken antiretrovirals)
• Kidney and liver health, and other co-existing medical conditions
• Other medicines you take (including OTC and herbal products)

7) Dosing and timing (general UK patient guidance)

Dosing depends on the specific formulation, age/weight (especially in children), and your treatment history. Always use the dose prescribed for you.

General timing considerations

• Kaletra is usually taken with regular dosing intervals to maintain steady drug levels.
• It is commonly taken twice daily for many adult regimens, but exact schedules may differ depending on local prescribing and formulation.
• Take with food as advised below to support absorption.

If you miss a dose

Follow your prescriber/pharmacist’s advice. In general:

• If you remember soon after the missed time, take it if close to your next dose as directed.
• If it is nearly time for the next dose, skip the missed dose and continue your usual schedule.
• Do not take double doses to make up for a missed one.

Tip: Set reminders (phone alarm, calendar) and keep a backup supply if possible.

8) Food interactions (what to eat and drink)

Food is important for Kaletra. Taking the medicine with food can improve absorption.

• Take with meals or a substantial snack, as advised for your formulation.
• Be consistent: try to take Kaletra at similar times each day with similar meal patterns.

If you have gastrointestinal upset (nausea, diarrhoea) or changes in appetite, tell your healthcare team—sometimes regimen timing or supportive treatment can help.

9) Alcohol and medicine interactions

Alcohol

Many people with HIV can drink alcohol, but with Kaletra it’s wise to be cautious:

• Alcohol can affect liver health, which is relevant because antiretrovirals are processed by the liver.
• Alcohol may worsen side effects such as nausea, dizziness or fatigue.
• If you have liver disease (for example hepatitis B or C co-infection), discuss alcohol with your clinician.

Alcohol-containing formulations

Some liquid formulations of medicines may contain alcohol or excipients. If you use the oral solution, check the product details or ask your pharmacist if alcohol content is a concern (for example pregnancy, liver issues, or treatment in children).

Major medicine interactions (important)

Kaletra can interact with many medicines because ritonavir affects CYP3A enzymes and other pathways. Some combinations can be dangerous or reduce Kaletra levels.

Tell your pharmacist/clinic about all medicines you take, including:

• Prescription medicines
• Pharmacy medicines (including cough/cold products)
• OTC pain relief (e.g., ibuprofen, paracetamol) and supplements
• Herbal products such as St John’s wort (commonly contraindicated with many HIV medicines)
• Recreational substances

Common interaction themes to be aware of

• Medicines whose levels change may increase side effects or reduce effectiveness.
• Some medicines are not recommended with Kaletra due to risk of serious effects or loss of viral suppression.
• Some antibiotics/antifungals, antidepressants, antiarrhythmics, antiepileptics, steroids, and cholesterol-lowering medicines can interact—your clinician will review your regimen.

Safety reminder: If you start or stop any medicine (including OTC products), check interactions with your pharmacy or HIV clinic.

10) Safety profile and monitoring

Like all medicines, Kaletra can cause side effects. Not everyone gets them, and many are manageable. Your healthcare team will monitor your health and advise when to report problems.

Common side effects

• Diarrhoea
• Nausea, vomiting, stomach discomfort
• Headache
• Rash
• Fatigue

Possible longer-term or clinically important effects

• Changes in blood fats (cholesterol and triglycerides): may require blood tests and diet/lifestyle advice
• Liver enzyme changes: routine blood tests may be performed
• Heart rhythm concerns in some circumstances: risk depends on the combination of medicines and individual factors
• Body fat changes (less common with modern regimens, but still a consideration)
• Metabolic effects: your team may monitor glucose and lipids

Serious warnings (seek urgent advice if necessary)

Contact urgent care or your clinic promptly if you experience:

• Signs of severe allergic reaction (swelling of face/lips, difficulty breathing)
• Severe skin reactions (widespread rash, blistering, peeling)
• Symptoms of liver problems (yellowing of eyes/skin, severe right-sided abdominal pain, dark urine)
• Severe or persistent diarrhoea with dehydration

Immune reconstitution inflammatory syndrome (IRIS)

When starting or changing HIV treatment, the immune system may recover and cause inflammatory symptoms due to existing infections. This is a known phenomenon with antiretroviral therapy and is assessed clinically. Tell your clinician about any new or worsening symptoms after starting treatment.

11) Practical use tips for patients

• Take with food as instructed to support absorption.
• Use a pill organiser if appropriate and confirmed with your pharmacist.
• Maintain consistent timing each day to avoid dips in drug levels.
• Do not stop Kaletra suddenly without medical advice—even brief interruption can risk viral rebound.
• Keep a written list of your medicines and show it to every new clinician.
• Check supplements and herbal products. “Natural” products can still interact with antiretrovirals.
• Manage side effects early: If diarrhoea or nausea occurs, contact your clinic rather than waiting.

12) Pharmacological interactions: alcohol, food, and other medicines

Below is a patient-friendly overview. For personalised interaction checking, always consult your pharmacy or clinic.

13) Monitoring and follow-up in the UK

Your clinician will typically monitor:

• Viral load to confirm suppression
• CD4 count and clinical status
• Blood tests including liver function and fasting lipids (cholesterol/triglycerides), and sometimes glucose
• Side effects and tolerance

In practice, monitoring schedules depend on your stability, past results, and co-existing conditions.

14) Alternative options

HIV treatment has several medicine classes. Whether Kaletra is the right choice depends on resistance, prior treatments, convenience, and interaction profile.

Possible alternative types of antiretrovirals (overview)

• Other protease inhibitors (some may be boosted or unboosted depending on the regimen)
• Integrase strand transfer inhibitors (INSTIs) (often used in modern UK regimens due to potency and tolerability)
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
• Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as part of a combination

Important: Switching HIV therapy requires careful review of your resistance history and interactions. Always discuss with an HIV specialist.

15) Market and legal context in the United Kingdom

In the UK, HIV medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and must meet standards for quality, safety and efficacy. Treatment is typically provided through NHS specialist services or accredited pathways, with prescribing and monitoring guided by national clinical recommendations.

Patients may access HIV care through:

• NHS HIV clinics
• Specialist commissioning pathways
• Managed treatment programmes depending on local area and funding

Online pharmacies in the UK typically follow legal requirements around supply, verification, and patient safety processes. Availability and the exact product presentation (capsules vs solution) may vary by supplier and demand.

16) Recent guidance (UK context)

UK HIV guidance is updated periodically by bodies such as NICE and the British HIV Association (BHIVA). Guidance commonly emphasises:

• Early diagnosis and treatment for eligible patients
• Use of effective combination regimens with consideration of resistance
• Minimising drug–drug interactions and optimising long-term tolerability
• Monitoring for metabolic and liver-related side effects

Your clinic will apply the most current guidance relevant to your situation. If you are switching regimens, your healthcare team may re-check interactions and prior resistance results.

17) Delivery and availability (UK online pharmacy experience)

Availability of Kaletra can differ by formulation and stock levels. Common considerations when ordering online include:

• Which presentation is available (capsules vs oral solution)
• Delivery timeframe shown at checkout
• Cold chain requirements (generally none for standard oral tablets/capsules, but check your product details)
• Packaging and privacy (many suppliers use discreet packaging)

For time-sensitive refills, order in advance of running out. If you are travelling or have an upcoming appointment, plan your supply accordingly.

18) Frequently Asked Questions (FAQ)

Is Kaletra the same as lopinavir?

Kaletra is a combination product containing lopinavir (200 mg) and ritonavir (50 mg) in each dose. Ritonavir “boosts” lopinavir by affecting drug metabolism.

Why is ritonavir included if it’s also an HIV medicine?

In Kaletra, ritonavir’s main role is to increase and stabilise lopinavir levels. It also has antiviral activity, but boosting is the key practical function in many regimens.

Should I take Kaletra with food?

In general, yes—food can improve absorption. Your exact instructions may depend on whether you are taking capsules or oral solution, and on your prescribed schedule.

Can I drink alcohol while taking Kaletra?

Many people choose to drink alcohol in moderation, but alcohol can worsen side effects and may affect the liver. If you have hepatitis B or C, liver problems, or you notice symptoms after drinking, ask your clinician for personalised advice.

What medicines should I avoid with Kaletra?

Many medicines can interact with Kaletra due to ritonavir’s effect on enzymes involved in drug metabolism. Avoid starting new medicines (including OTC and herbal products like St John’s wort) without checking. Your pharmacist can help with an interaction review.

What should I do if I miss a dose?

Follow the guidance provided by your clinic or pharmacist. Avoid taking double doses to compensate. If you’re unsure, contact your pharmacy or HIV clinic for advice.

What side effects are most common?

Common side effects include gastrointestinal symptoms (such as diarrhoea and nausea) and headache. If side effects are severe, persistent, or you feel unwell, contact your healthcare team promptly.

Will Kaletra cure HIV?

Kaletra helps control HIV by reducing viral replication, but it is not a cure. With ongoing treatment, many people achieve and maintain viral suppression.

How will I know the treatment is working?

Your HIV clinic will monitor your viral load and CD4 count. A low or undetectable viral load indicates effective suppression.

Can I stop Kaletra if I feel better?

No—feelings of wellbeing do not confirm viral control. Stopping treatment can lead to viral rebound and resistance. Discuss any changes with your clinician.

Are there alternatives if Kaletra doesn’t suit me?

Yes. There are other antiretroviral options and other combinations. Your suitability depends on your history, resistance profile, and interaction considerations.

19) Summary

Kaletra (lopinavir 200 mg/ritonavir 50 mg) is an HIV protease inhibitor combination used to treat HIV-1 infection as part of combination therapy. It works by blocking HIV protease to prevent formation of infectious virus, while ritonavir boosts lopinavir exposure. Food can improve absorption, while alcohol and many medicines may interact due to ritonavir’s strong influence on liver enzymes. Regular monitoring for viral load, immune status, and common safety parameters—particularly liver function and blood fats—is important for safe, effective treatment.

If you have questions about how Kaletra fits your specific regimen, or if you’re concerned about interactions or side effects, speak with your HIV clinic or pharmacist for personalised guidance.